David Kay, MD
Glaucoma Specialist · Mesa, AZNPI 1487067484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 24.4% of the total.
Across 144 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Glaukos Corporation$961
- Novartis$625
- Alcon$453
- Sight Sciences, Inc.$219
- Johnson & Johnson Surgical Vision, Inc.$141
- plus $732 from 14 others
What the payments were for
- Food & beverage$4,11199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $1,012 |
| Glaukos Corporation | 11 | $961 |
| Novartis | 13 | $625 |
| Alcon | 11 | $453 |
| Sight Sciences, Inc. | 6 | $219 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $141 |
| Bausch & Lomb Americas Inc. | 5 | $94 |
| Aerie Pharmaceuticals, Inc. | 4 | $82 |
| Genentech USA, Inc. | 1 | $81 |
| Thea Pharma Inc. | 4 | $73 |
| NEW World Medical,inc. | 4 | $68 |
| Angiodynamics, Inc. | 1 | $61 |
| Carl Zeiss Meditec, Inc. | 1 | $57 |
| Tarsus Pharmaceuticals, Inc. | 2 | $50 |
| Akorn Operating Company LLC | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Rxsight Inc | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$443
- TRAVATAN Z$238
- iDose$191
- AcrySof IQ VIVITY IOL$139
- XEN GLAUCOMA TREATMENT SYSTEM$117
- iStent Infinite$108
How this compares
Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 137 | $82,307 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $10,870 |
| Prednisolone Acetate | 265 | $9,577 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $9,383 |
| Alphagan PBrimonidine Tartrate | 23 | $8,706 |
| VyzultaLatanoprostene Bunod | 13 | $5,614 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $4,082 |
| Travoprost | 21 | $2,406 |
| Latanoprost | 153 | $1,780 |
| Brimonidine Tartrate | 47 | $1,415 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $1,167 |
| MoxifloxacinMoxifloxacin Hcl | 64 | $949 |
| Ketorolac Tromethamine | 20 | $759 |
| Pilocarpine Hcl | 18 | $722 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $1,012 | $100,396178 claims |
| AlconSimbrinza | $453 | $10,87039 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $94 | $5,61413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Mesa
- John LewisMesa$61K
- Robert SpurnyMesa$5K
- Christine FunkePhoenix$255K
- Max KimPhoenix$10K
- Trenton BowenGilbert$4K
- Michael CampionScottsdale$3K
- Neil AtodariaPhoenix$3K
- Sunil DeokuleYuma$2K
- Tara GolischPhoenix$2K
- Brian ChangCottonwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.